Lilly to supply additional 150K doses of AbCellera's bebtelovimab for ~$275M

AbCellera Biologics Inc.

Eli Lilly modified agreement with U.S. government for 150,000 additional doses of bebtelovimab at ~$275M.
Delivery begins immediately and completes by August 5, 2022; option for 350,000 more doses by Sep 14, 2022.
Bebtelovimab maintains neutralization against Omicron variants BA.2.12.1 and BA.4/BA.5, plus all known variants.
Existing supply plus new purchase expected to meet U.S. demand through late August 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.